Be on the lookout for a price bounce soon.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Moving Average Convergence Divergence (MACD) for MGNX just turned positive on November 10, 2026. Looking at past instances where MGNX's MACD turned positive, the stock continued to rise in 39 of 51 cases over the following month. The odds of a continued upward trend are 76%.
Following a +3.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where MGNX advanced for three days, in 228 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
MGNX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MGNX as a result. In 79 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The 50-day moving average for MGNX moved below the 200-day moving average on November 11, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MGNX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for MGNX entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. MGNX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.462) is normal, around the industry mean (3.596). P/E Ratio (-10.591) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (10.770) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (1.477) is also within normal values, averaging (443.347).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MGNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
It is expected that a price bounce should occur soon.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where TENX advanced for three days, in 191 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
TENX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TENX as a result. In 73 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
The Moving Average Convergence Divergence Histogram (MACD) for TENX turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 35 similar instances when the indicator turned negative. In 27 of the 35 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.
TENX moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TENX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for TENX entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.557) is normal, around the industry mean (3.596). P/E Ratio (-1.142) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. TENX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TENX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
MGNX | TENX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 88 Overvalued | 38 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 98 | |
PRICE GROWTH RATING 1..100 | 65 | 87 | |
P/E GROWTH RATING 1..100 | 11 | 6 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TENX's Valuation (38) in the Medical Specialties industry is somewhat better than the same rating for MGNX (88) in the Biotechnology industry. This means that TENX’s stock grew somewhat faster than MGNX’s over the last 12 months.
TENX's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as MGNX (100) in the Biotechnology industry. This means that TENX’s stock grew similarly to MGNX’s over the last 12 months.
MGNX's SMR Rating (97) in the Biotechnology industry is in the same range as TENX (98) in the Medical Specialties industry. This means that MGNX’s stock grew similarly to TENX’s over the last 12 months.
MGNX's Price Growth Rating (65) in the Biotechnology industry is in the same range as TENX (87) in the Medical Specialties industry. This means that MGNX’s stock grew similarly to TENX’s over the last 12 months.
TENX's P/E Growth Rating (6) in the Medical Specialties industry is in the same range as MGNX (11) in the Biotechnology industry. This means that TENX’s stock grew similarly to MGNX’s over the last 12 months.
| MGNX | TENX | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 79% | 3 days ago 90% |
| Stochastic ODDS (%) | 3 days ago 85% | 3 days ago 87% |
| Momentum ODDS (%) | 3 days ago 87% | 3 days ago 79% |
| MACD ODDS (%) | 3 days ago 76% | 3 days ago 77% |
| TrendWeek ODDS (%) | 3 days ago 86% | 3 days ago 88% |
| TrendMonth ODDS (%) | 3 days ago 87% | 3 days ago 88% |
| Advances ODDS (%) | 13 days ago 84% | 14 days ago 82% |
| Declines ODDS (%) | 5 days ago 84% | 3 days ago 87% |
| BollingerBands ODDS (%) | 3 days ago 79% | 3 days ago 88% |
| Aroon ODDS (%) | 3 days ago 90% | 7 days ago 89% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MGNX’s FA Score shows that 1 FA rating(s) are green while TENX’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MGNX’s TA Score shows that 5 TA indicator(s) are bullish while TENX’s TA Score has 4 bullish TA indicator(s).
MGNX (@Biotechnology) experienced а -10.91% price change this week, while TENX (@Biotechnology) price change was -22.84% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -11.58%. For the same industry, the average monthly price growth was -18.26%, and the average quarterly price growth was -28.15%.
MGNX is expected to report earnings on Feb 25, 2027.
TENX is expected to report earnings on Apr 01, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, MGNX has been loosely correlated with KRRO. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MGNX jumps, then KRRO could also see price increases.
| Ticker / NAME | Correlation To MGNX | 1D Price Change % | ||
|---|---|---|---|---|
| MGNX | 100% | -1.01% | ||
| KRRO - MGNX | 45% Loosely correlated | -0.08% | ||
| AMRN - MGNX | 44% Loosely correlated | -6.13% | ||
| VYGR - MGNX | 40% Loosely correlated | -4.97% | ||
| AARD - MGNX | 39% Loosely correlated | -7.74% | ||
| ZVRA - MGNX | 38% Loosely correlated | -3.42% | ||
More | ||||
A.I.dvisor indicates that over the last year, TENX has been closely correlated with SION. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if TENX jumps, then SION could also see price increases.
| Ticker / NAME | Correlation To TENX | 1D Price Change % | ||
|---|---|---|---|---|
| TENX | 100% | -10.07% | ||
| SION - TENX | 93% Closely correlated | -4.88% | ||
| AVXL - TENX | 47% Loosely correlated | -11.39% | ||
| CORT - TENX | 41% Loosely correlated | -2.09% | ||
| HRTX - TENX | 40% Loosely correlated | -4.39% | ||
| MGNX - TENX | 32% Poorly correlated | -1.01% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IBND | 29.09 | 0.01 | +0.03% |
| State Street SPDR Bloomberg International Corporate Bond ETF (IBND) | |||
| SNPD | 30.74 | N/A | N/A |
| Xtrackers S&P Dividend Aristocrats Screened ETF (SNPD) | |||
| ECML | 40.07 | N/A | N/A |
| Euclidean Fundamental Value ETF (ECML) | |||
| ISWN | 20.18 | -0.19 | -0.94% |
| Amplify BlackSwan ISWN ETF (ISWN) | |||
| PTY | 10.21 | -0.12 | -1.16% |
| PIMCO Corporate & Income Opportunity Fund | |||